AIM ImmunoTech targets Q1 2027 topline data for Phase 2 DURIPANC trial of Ampligen plus AstraZeneca’s Imfinzi in pancreatic cancer

• AIM ImmunoTech highlighted Ampligen’s potential role in pancreatic cancer, including use alone or in combination with other therapies.
• Prior data from a Dutch named-patient program were cited as showing longer survival for selected patients versus historical controls, without detailing new trial results.
• A Phase 2 DURIPANC study testing Ampligen with AstraZeneca’s Imfinzi is ongoing in patients with stable disease following FOLFIRINOX.
• Topline DURIPANC results are expected in Q1 2027, with a more detailed overall-survival analysis slated for Q3 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220855OMX_____CNEWS_EN_GNW9830852_en) on September 22, 2026, and is solely responsible for the information contained therein.